MPEP § 2422.08 — Presumptions Regarding Compliance (Annotated Rules)

§2422.08 Presumptions Regarding Compliance

USPTO MPEP version: BlueIron's Update: 2025-12-31

This page consolidates and annotates all enforceable requirements under MPEP § 2422.08, including statutory authority, regulatory rules, examiner guidance, and practice notes. It is provided as guidance, with links to the ground truth sources. This is information only, it is not legal advice.

Presumptions Regarding Compliance

This section addresses Presumptions Regarding Compliance. Primary authority: 35 U.S.C. 112, 37 CFR 1.821, and 37 CFR 1.825. Contains: 1 requirement and 1 other statement.

Key Rules

Topic

Sequence Listing Format

2 rules
StatutoryRequiredAlways
[mpep-2422-08-4065caff115585c9a9dc1c05]
Sequence Listing Not Presumed Necessary
Note:
The presence or absence of sequence information not required by the sequence rules does not create a presumption that such information is necessary to satisfy the requirements of 35 U.S.C. 112.

Neither the presence nor absence of information which is not required under the sequence rules will create a presumption that such information is necessary to satisfy any of the requirements of 35 U.S.C. 112. Further, the grant of a patent on an application that is subject to 37 CFR 1.821 through 37 CFR 1.825 constitutes a presumption that the granted patent complies with the requirements of these rules.

Jump to MPEP Source · 37 CFR 1.821Sequence Listing FormatSequence Listing RequirementsDisclosure Requirements
StatutoryInformativeAlways
[mpep-2422-08-52d7d28337b29ee0ce789b75]
Patent Grant Presumes Compliance with Sequence Rules
Note:
The grant of a patent on an application that follows the sequence listing rules presumes compliance with those requirements.

Neither the presence nor absence of information which is not required under the sequence rules will create a presumption that such information is necessary to satisfy any of the requirements of 35 U.S.C. 112. Further, the grant of a patent on an application that is subject to 37 CFR 1.821 through 37 CFR 1.825 constitutes a presumption that the granted patent complies with the requirements of these rules.

Jump to MPEP Source · 37 CFR 1.821Sequence Listing FormatSequence Listing RequirementsDisclosure Requirements
Topic

Sequence Listing Content

1 rules
StatutoryInformativeAlways
[mpep-2422-08-d63cdbc6b88bd41f2ffa274d]
Requirement for Nucleotide and Amino Acid Sequence Disclosures Post July 1, 2022
Note:
This rule requires disclosures of nucleotide and amino acid sequences in applications filed after July 1, 2022, as defined by 37 CFR 1.831(b). For earlier filings, refer to MPEP sections 2412-2419 for guidance on WIPO ST.26 requirements.

[Editor Note: This section is not applicable to applications filed on or after July 1, 2022, having disclosures of nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b). See MPEP §§ 2412 – 2419 for guidance on WIPO ST.26 requirements for applications filed on or after July 1, 2022.]

37 CFR 1.77 · 37 CFR 1.831(b)Sequence Listing ContentSequence Listing Requirements

Citations

Primary topicCitation
Sequence Listing Format35 U.S.C. § 112
Sequence Listing Format37 CFR § 1.821
Sequence Listing Format37 CFR § 1.825
Sequence Listing Content37 CFR § 1.831(b)
Sequence Listing ContentMPEP § 2412

Source Text from USPTO’s MPEP

This is an exact copy of the MPEP from the USPTO. It is here for your reference to see the section in context.

BlueIron Last Updated: 2025-12-31